Alpha Cancer Technologies Inc. reports acceptance of the abstract of study of ACT-101 in a model of inflammatory bowel disease to the World Congress of Gastroenterology at ACG 2017

Toronto, Canada  June 15, 2017  — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that the abstract describing the results of a preclinical study of the efficacy of ACT-101 in a mouse model of inflammatory bowel disease (IBD) has been submitted for presentation at the World Congress of Gastroenterology at ACG 2017 to be held in Orlando, Florida October 13-18, 2017.

The study was conducted at Intestinal Biotech Development, Lille Medical School, France, one of the premier research centres specializing in animal models of IBD. The study compared the effect of ACT-101 to placebo and anti-TNFα, current state of the art therapy, in a model of colitis induced by Trinitrobenzenesulfonic acid (TNBS) infusion in the colon. This model is considered to be one of the best models for testing potential therapeutic agents for the treatment of IBD.

The study results are to be presented by Pierre Desreumaux, MD, PhD., Chief Scientific Officer at Intestinal Biotech Development. Dr. Desreumaux is an eminent gastroenterologist and a Professor in the Department of Gastroenterology and Nutrition of the University Hospital of Lille and the head of the Research Unit on the Pathophysiology of Inflammatory Bowel Diseases (IBD). He was elected as "the best clinical researcher" by the National Medical Research Institute (INSERM, France) and is the founder of DIGESTSCIENCE, a Foundation for research in Digestive Tract and Nutrition Diseases.

Study abstract will be published in October issue of Gastroenterology.

"We are pleased to be able to have our findings accepted for distribution to the international community of gastroenterologists. We are continuing our development efforts with this novel therapy for autoimmune diseases looking to corroborate previously reported positive clinical data in a small study in this disease using native human AFP" stated Dr. Pierre Desreumaux, M.D., Ph.D. [1]


All findings are strictly embargoed until October 16, 2017 at 8:00 am EDT.

About Alpha Cancer Technologies Inc.

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in autoimmune and oncology disease indications. The company’s drug products use proprietary recombinant human alpha fetoprotein (ACT-101 or AFP) to directly impact autoimmune diseases (myasthenia gravis, Inflammatory Bowel Disease (Crohn's/Colitis), Hashimoto disease) and uses AFP to carry chemotherapy agents (ACT-901, 902, 903) targeted directly to AFP receptors found on most cancer cells.

ACT-101 has received Orphan Drug Designation for the treatment of myasthenia gravis from the U.S. Food and Drug Administration (FDA).

ACT has exclusive worldwide rights to its proprietary recombinant human AFP with over $100 million spent on the development of the in-licensed technology. Clinical studies of ACT-101 have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.

Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities legislation (collectively, the "forward-looking statements"). These forward-looking statements relate to, among other things, ACT’s
objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management.

Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to, the availability of capital, changes in capital markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, unproven markets for technologies in development, the cost and supply of raw materials, management of growth, effects of payers' willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.

For more information please visit www.alpha-cancer.com or contact:

Richard Potts  
Chairman  
Alpha Cancer Technologies Inc.  
Tel: +1 (416) 464-2678  
Email: rponds@alpha-cancer.com

Igor Sherman Ph. D.  
President & CEO  
Alpha Cancer Technologies Inc.  
Tel: +1 (416) 826-6626  
Email: isherman@alpha-cancer.com

Vasilios Kofitsas  
Senior Director  
Back Bay Life Science Advisors  
Tel: +1(617) 933-5821  
vkofitsas@bblsa.com